Vaccine Manufacture and Supply – News and Features

Baxter has started full-scale production of a commercial A/H1N1 vaccine using its Vero cell culture technology.

Clinical data from a Phase III and subsequent booster study demonstrate safety, immune response and cross-protective memory.

Novavax, Inc. announced today favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax's VLP candidate is directed against the H5N1 A/Indonesia/05/2005 avian influenza strain.

Researchers have figured out a way to genetically disarm the virus and making the agent safe to study under conditions far less stringent than those currently imposed.

The £1million facility will produce clinical trial material manufactured to the approved quality.